FDA approves Horizon's Rayos

FDA approved an NDA from Horizon Pharma Inc. (NASDAQ:HZNP) for Rayos prednisone delayed-release tablets to treat a broad range of diseases, including rheumatoid arthritis (RA), polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma and chronic obstructive pulmonary disease (COPD). Horizon plans to launch Rayos next quarter. ...